Achieve Life Sciences reports positive Phase 3 ORCA-3 data; 12-week cytisinicline 30.3% quit rate vs 9.4% placebo

ACHIEVE LIFE SCIENCES, INC.

12-week cytisinicline: 30.3% quit rate last 4 wks, 4.4x odds vs placebo (p<0.0001); continuous abstinence wk9-24: 20.5% vs 4.2%
6-week cytisinicline: 14.8% quit rate last 4 wks, 2.85x odds vs placebo (p=0.0008); continuous abstinence wk3-24: 6.8% vs 1.1%
No treatment-related serious adverse events; common side effects: insomnia (11.9% 12-wk), abnormal dreams, nausea, headache
ORCA-3 enrolled 792 adult smokers at 20 US sites; results consistent with prior Phase 3 ORCA-2 study
Cytisinicline could be first new prescription smoking cessation treatment in ~20 years; conference call May 23 at 8:30AM EDT

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.